logo

Loading..
English
  • Svenska
EN
  • SV
Loading..
logo
English
  • Svenska
  • About the company
    About the company
      • Company in brief
      • Company history
      • Strategy and IP
      • Organisation
      • Founders
      • The Board
      • Management
      • Clinical Advisory Board
  • About melflufen
    About melflufen
      • About melflufen
      • Mechanism of action
      • About Multiple Myeloma
      • About our research
        • Selected bibliography
  • Our clinical trials
    Our clinical trials
      • Summary
      • O-12-M1
      • HORIZON
      • OCEAN
      • ANCHOR
      • BRIDGE
  • Investors & media
    Investors & media
      • Share issue June 2019
      • Share issue January 2019
      • Share issue March 2018
      • Prospectus
      • The share
        • Share capital development
        • Dividend policy
        • Ownership structure
        • Analysts
      • Financial reports
      • Presentations
      • Press releases
      • News
      • Calendar
      • Subscribe
      • Image bank
      • Investors & media contact
  • Corporate governance
    Corporate governance
      • Corporate Governance Reports
      • Governance structure
      • General meeting
        • Annual General Meeting 2019
        • General Meetings
      • Nomination committee
        • Nomination Committee 2019
      • The Board of Directors
        • Board of Directors
        • Work of the Board of Directors
        • Board committees
      • Management
        • Group Management
      • Remuneration
      • Auditors
      • Internal control
      • Articles of association
  • Contact
    Contact
      • Office
      • Investors & media
      • Career at Oncopeptides AB
Investors & mediaNewsOncopeptides Receives the SwedenBIO Award 2017

Oncopeptides Receives the SwedenBIO Award 2017

May 17, 2017 News

For the 11th time, SwedenBIO Award was awarded on Wednesday night.

This year’s winner is Oncopeptides AB. They are praised for their work on developing treatment for haematological cancer.

Links

  • Press release SwedenBIO - Oncopeptides vinnare av SwedenBIO Award 2017 - In Swedish

Interim Report Q1 2019

Oncopeptides AB released its Interim Report Q1 2019 on May 21, 2019.

  • Report
  • Press release
  • Audiocast
Read the report

Calendar

  • Interim Report Q2 2019 August 28, 2019
  • Presenting at Pareto Securities 10th Annual Healthcare Conference September 5, 2019
  • Presenting at Pareto Securities 10th Annual Healthcare Conference September 5, 2019
  • Interim Report Q3 2019 November 19, 2019
All events

Subscribe

  • Investors & media
    • Share issue June 2019
    • Share issue January 2019
    • Share issue March 2018
    • Prospectus
    • The share
      • Share capital development
      • Dividend policy
      • Ownership structure
      • Analysts
    • Financial reports
    • Presentations
    • Press releases
    • News
    • Calendar
    • Subscribe
    • Image bank
    • Investors & media contact
Share
About the company
  • Company in brief
  • Company history
  • Strategy and IP
  • Organisation
  • Founders
  • The Board
  • Management
About melflufen
  • About melflufen
  • Mechanism of action
  • About Multiple Myeloma
  • About our research
Our clinical trials
  • Summary
  • O-12-M1
  • HORIZON
  • OCEAN
  • ANCHOR
  • BRIDGE
Investors & media
  • Share issue June 2019
  • Share issue January 2019
  • Share issue March 2018
  • Prospectus
  • The share
  • Financial reports
  • Presentations
  • Press releases
  • News
  • Calendar
  • Subscribe
  • Image bank
  • Investors & media contact
Corporate governance
  • Corporate Governance Reports
  • Governance structure
  • General meeting
  • Nomination committee
  • The Board of Directors
  • Management
  • Remuneration
  • Auditors
  • Internal control
  • Articles of association
Contact
  • Office
  • Investors & media
  • Career at Oncopeptides AB
  • Oncopeptides AB
  • Visiting and mail address: Luntmakargatan 46, SE-111 37 Stockholm, Sweden
  • Visiting and Mail address, US Inc: 444 Castro Street, Mountain View, CA 94041, USA
  • Legal address: Västra Trädgårdsgatan 15, SE-111 53 Stockholm, Sweden
  • E-mail: info@oncopeptides.com
  • Registration number: 556596-6438
  • About cookies
  • Personal Data and General Data Protection Regulation (GDPR)
Back to top

Welcome to Oncopeptides AB’s (publ) website. In order to optimize your use of our website we use cookies. A cookie is a text file stored on your computer. If you want more information about what a cookie is, what the purpose of the cookie is and how you can block or delete cookies, please read the our cookie guidelines “About cookies”. By continuing, you agree to our use of cookies.

Close